| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_460ac56766516d38aa02f27b21b531e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e6699668f3c96b7126d60467c2798c4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-773
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-906
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S977-907 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate |
2012-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6243843263a2f576b93460f841fef476 |
| publicationDate |
2012-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2012308643-A1 |
| titleOfInvention |
Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
| abstract |
Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238602-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017312366-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018075801-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9393198-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10449193-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9138411-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10117881-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357458-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019531309-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10532045-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015164878-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3528848-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10617639-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9682041-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10349884-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017257496-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2020213354-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011229555-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021500318-A |
| priorityDate |
2011-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |